Adenosine Receptor A3 ADORA3 Pipeline Review, H1 2018
Summary
Adenosine Receptor A3 ADORA3 The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G proteincoupled receptors that mediates a sustained cardioprotective function during cardiac ischemia.
It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor A3AR is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy.
Adenosine Receptor A3 ADORA3 pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 1, 8, 4 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Ophthalmology, Gastrointestinal, Genito Urinary System And Sex Hormones, Toxicology, Central Nervous System, Dermatology, Hematological Disorders, Male Health, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Glaucoma, Rheumatoid Arthritis, NonAlcoholic Steatohepatitis NASH, Solid Tumor, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Arthritis, Asthma, Atopic Dermatitis, Chemotherapy Induced Pain, Chemotherapy Induced Peripheral Neuropathy, Chronic Obstructive Pulmonary Disease COPD, Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Glomerulonephritis, Hepatocellular Carcinoma, Idiopathic Thrombocytopenic Purpura Immune Thrombocytopenic Purpura, Inflammation, Irritable Bowel Syndrome, Kidney Fibrosis, Lupus Erythematosus, Melanoma, Neuropathic Pain, Non Alcoholic Fatty Liver Disease NAFLD, Ocular Hypertension, OpenAngle Glaucoma, Plaque Psoriasis Psoriasis Vulgaris, Prostate Cancer, Psoriasis and Pulmonary Fibrosis.
The latest report Adenosine Receptor A3 ADORA3 Pipeline Review, H1 2018, outlays comprehensive information on the Adenosine Receptor A3 ADORA3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Adenosine Receptor A3 ADORA3 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 ADORA3
The report reviews Adenosine Receptor A3 ADORA3 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Adenosine Receptor A3 ADORA3 targeted therapeutics and enlists all their major and minor projects
The report assesses Adenosine Receptor A3 ADORA3 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Adenosine Receptor A3 ADORA3 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 ADORA3
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 ADORA3 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Original Article: Adenosine Receptor A3 ADORA3 Pipeline Review, H1 2018 [Report Updated: 13032018] Prices from USD $3500
NEXT ARTICLE